Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease characterized by rhinosinusitis and the development of polyposis originating in the sinus and eventually extending to the nose. Persistent symptoms include congestion, stuffiness, nasal discharge, facial pain and/or pressure, impairment, or loss of sense of smell, and fatigue. CRSwNP confers a substantial but often underappreciated burden, negatively impacting mental and physical health-related quality of life (HRQoL) endpoints. To help alleviate this burden clinicians need to recognize the impact of CRSwNP and its many comorbidities on patients’ HRQoL and understand how the severity of CRSwNP can affect treatment response and duration.
In part one of this CMEO Snack series on CRSwNP, join Dr. Han and Dr. Lee as they discuss strategies for how clinicians can better recognize and understand the impact of the burden posed by CRSwNP.
At the end of this CME/CE activity, participants should be able to recognize the burden of CRSwNP and the impact of this disease on patients’ HRQoL and treatment response.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Han reports the following financial relationships: Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme
Dr. Lee reports the following financial relationships: Consultant and Research Support: AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Sanofi Regeneron
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).